Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load

Hepatology Research

Volumn 37, Issue 10, 2007, Pages 787-792

  Sezaki, Hitomi ^a   Suzuki, Fumitaka ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

ALT; Chronic hepatitis C; Combination therapy; Non responder; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA2B INTERFERON; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PREVENTION; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS CARCINOGENESIS; VIRUS LOAD;

EID: 34548192075     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00132.x     Document Type: Article

References (24)

1. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
2. Ikeda K, Saitoh S, Suzuki Y et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-33.
4. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 329: 1124-30.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
6. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
7. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
8. Reichard O, Norkrans G, Frydén A et al. Randomised double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
9. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
10. Iino S, Tomita E, Kumada H et al. Impact of daily high-dose IFN α-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV-RNA levels. Hepatol Res 2005; 31: 88-94.
11. Chayama K, Tsubota A, Arase Y et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993; 8: 150-6.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
13. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok ASF. Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naïve chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004; 2: 425-31.
14. Tsubota A, Arase Y, Someya T et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 27-34.
15. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
16. Akuta N, Suzuki F, Sezaki H et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
17. Akuta N, Suzuki F, Tsubota A et al. Efficacy of interferon monotherapy to 394 consecutive naïve cases infected with hepatitis C virus genotype 2a in Japan: Therapy efficacy as consequence of tripartite interferon of viral, host and interferon treatment-related factors. J Hepatol 2002; 37: 831-6.
18. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-9.
19. Berg T, Von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
20. Iino S. Incidence of Progression to Hepatocellular Carcinoma Following Interferon Treatment of Chronic Hepatitis C Using a Survey by Questionnaire. Annual report from Non-A, Non-B Hepatitis Research Group sponsored ministry of Health and Welfare, Tokyo. 1997; 49-52 (in Japanese).
21. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.
22. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 285-93.
23. Ikeda K, Arase Y, Saitoh S et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: A large-scale long-term study in a single center. Intervirology 2006; 49: 82-90.
24. Akuta N, Suzuki F, Suzuki Y et al. Long-term follow-up of interferon monotherapy in 454 consecutive naïve patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40: 688-96.